Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 10/20 | 0.42 |
| ▸ | FNTB | P49356 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499471 | 0.85 | FNTA (0.44) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3500364 | 0.83 | TSHR (0.48) | KDM4EFNTAFNTBALDH1A1MEN1 | |
| Trifluoroacetic Acid SCHEMBL5583305 | 0.80 | FNTA (0.42) | FNTAFNTBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL3502116 | 0.79 | FNTA (0.45) | KDM4EFNTAFNTBALDH1A1SMN1; SMN2 | |
| SCHEMBL3499472 | 0.78 | FNTA (0.49) | KDM4EFNTAFNTBMEN1KMT2A | |
| SCHEMBL3499620 | 0.77 | CACNA1G (0.47) | MAPTFNTAFNTBSMN1; SMN2CACNA1G | |
| SCHEMBL3500085 | 0.76 | FNTA (0.45) | KDM4EMAPTFNTAFNTBALDH1A1 | |
| SCHEMBL2364392 | 0.76 | FNTA (0.68) | FNTAFNTB | |
| SCHEMBL3501053 | 0.75 | TSHR (0.45) | KDM4EMAPTFNTAFNTBALDH1A1 | |
| SCHEMBL3500544 | 0.75 | FNTA (0.46) | KDM4EFNTAFNTBALDH1A1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| EP-0892797-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-10-20 | — | — | EP | claimed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | claimed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050288257-A1 | Novel stable compositions of water and oxygen sensitive compounds and their method of preparation | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-12-29 | — | — | US | disclosed |
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | L3MBTL1 956/4885ATM 3189/4885KDM4E 3915/4885 |
| US-20050288257-A1 | Novel stable compositions of water and oxygen sensitive compounds and their method of preparation | COXFA4L2, CYP2F1, ABCG2 | L3MBTL1 4766/4885ATM 363/4885KDM4E 1422/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | L3MBTL1 754/4885ATM 3261/4885KDM4E 3399/4885 |
| US-20070293539-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | L3MBTL1 956/4885ATM 3189/4885KDM4E 3915/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | L3MBTL1 2294/4885ATM 2009/4885KDM4E 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.